Compassionate Use of Pozelimab

Regeneron Pharmaceuticals

Status

Conditions: CD55-deficient Protein-losing Enteropathy

Treatments: Drug: Pozelimab

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT05232110

R3918-Pozelimab

Details and patient eligibility

About

Provide compassionate use of pozelimab

Full description

Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications.

Sex

Volunteers: No Healthy Volunteers

Inclusion criteria

-

Exclusion criteria

-